Companies › Pharmasoft
2 active drug programs in 2 registered trials: 2 Phase 4; Neurology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Glycine Glycine receptor agonist | GLRA1 | Phase 4 | Ischemic Stroke | Apr 2027 |
| Mexidol Antioxidant and neuroprotective agent | – | Phase 4 | Ischemic Stroke | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07575984 | Mexidol | Phase 4 | Ischemic Stroke | Neurology | Apr 2027 |
| NCT07575984 | Glycine | Phase 4 | Ischemic Stroke | Neurology | Apr 2027 |
Suven Life Sciences Bigespas JYAMS PET Research & Development Longboard Pharmaceuticals TriGemX Bio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.